Cohort Study to Evaluate Ovarian Function

Multicenter Cohort Study to Evaluate and to Protect Ovarian Function and Reproductive Function

The study will collect the clinical and biological data of the patients, the investigators could further analyse and identify the risk factors and optimize clinical treatment method. Besides, population-based healthy people with informed consent are also collected.

Study Overview

• Status: Unknown
• Conditions: Cardiovascular Diseases; Menopausal Syndrome; Female Infertility Due to Diminished Ovarian Reserve; Sexual Function and Fertility Disorders

Detailed Description

Menopause is the last step in the process of ovarian ageing. Decrease in follicle numbers dictates the onset of cycle irregularity and the cessation of menses. At the same time, decaying in oocyte quality contributes to the gradual decline in fertility. Endocrine changes mainly depend on the decline in the negative feedback by ovarian factors at the hypothalamo-pituitary unit. The declining antral follicle cohort(AFC) with age first results in gradually elevated FSH levels. The gradual decline in the size of AFC is best represented by decreasing levels of anti-Mullerian hormone. The identification of women who have severely decreased ovarian reserve is clinically relevant. Ovarian reserve tests have appeared to be fairly accurate in predicting response to ovarian stimulation in the assisted reproductive technology (ART) setting. The capacity to predict the chances for spontaneous pregnancy or pregnancy after ART appears very limited. As menopause and the preceding decline in oocyte quality seem to have a fixed time interval, tests that predict the age at menopause may be useful to assess individual reproductive lifespan like genetic studies, ovarian ageing mechanism studies and epigenetic studies.

Heart disease remains a major cause of death among women in China. We focuses on physiologic endogenous sex steroid levels and heart disease especially for CAD among postmenopausal women with natural or surgical menopause. Now there are more and more reasons to seek evidence for associations of circulating estrogen or other endogenous sex steroid levels and CAD. In the future, we design a cohort study to confirm whether ovarian sex steroid hormonal changes is associated with CAD postmenopausal women, or there may be other components explaining the gender differences in CAD patterns.

Premature ovarian failure(POF), is a disorder of infertility characterized by amenorrhoea, low estrogen levels and increased gonadotropin levels in women aged <40 years. POF is the result of premature exhaustion of the follicle pool or can be attributed to follicular dysfunction, for example, owing to mutations in the FSH receptor or steroidogenic cell autoimmunity. Moreover, advances in cancer therapeutics over the past decades have led to increasing survival rates for both paediatric and adult malignancies. Given the gonadotoxic effect of many cancer treatments, more women develop POF. Markers that predict whether women are at risk of POF would, therefore, aid in early diagnosis and fertility counselling.

The history of past and present status has been taken in our research. Women on the process of natural aging and disease-induced ovarian aging are all included. The key factors that influence ovary aging may be identified by epidemiological and molecular biological research.

• Study Type: Observational
• Enrollment (Anticipated): 6000

Contacts and Locations

• Study Contact: Name: Shixuan Wang; Phone Number: 86-27-8366-3078; Email: sxwang2012@hotmail.com

Study Locations

• China
  • Hubei
    • Wuhan, Hubei, China, 430000
      • Recruiting
      • Huazhong University of Science and Technology
      • Contact: Shixuan Wang, MD. PhD.; Phone Number: 86-27-8366-3078; Email: sxwang2012@hotmail.com
      • Sub-Investigator: Kecheng Huang, MD
      • Sub-Investigator: Xiaofang Du, MD
      • Sub-Investigator: Ting Ding, PhD
      • Sub-Investigator: Aiyue Luo, PhD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: Female

• Sampling Method: Probability Sample

Study Population

women with normal ovarian function or decreased ovarian function

Description

Inclusion Criteria:

• Karnofsky Performance Statue ≥ 70,
• WBC > 3,000/mm³,
• Hb > 9.0g/dl,
• Platelet > 100,000 /mm³,
• SGOT/SGPT < 60 IU/L,
• T-Bil < 1.5 mg/dL,
• Cr < 1.2 mg/dL,
• PaO2 > 80 torr,
• normal ECG,
• Written informed consent.

Exclusion Criteria:

• Patients without information,
• clinical risk factors,
• Patients who have active infection.

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
ovarian function evaluation including parameters FSH(mIu/ml), LH(mIu/ml), E2(pg/ml), T(ng/dl) for individuals with normal ovarian function (more than 2 000 women) and ovarian failure(more than 1 000 women).	FSH(mIu/ml), LH(mIu/ml), E2(pg/ml), T(ng/dl) levels were measured using a chemiluminescence-based immunometric assay on an ADVIA Centaur immunoassay system (Siemens Healthcare Diagnostics Inc., Tarrytown, NY, USA).	up to 3 year

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
women's reproductive function including pregnancy rate	pregnancy rate was recorded once a year	up to 3 year

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
ovarian function including parameters FSH(mIu/ml), LH(mIu/ml), E2(pg/ml) and T(ng/dl) and reproductive function including pregnancy rate after treatment for young female patients who have benign or malignant tumor	FSH(mIu/ml), LH(mIu/ml), E2(pg/ml) and T(ng/dl) levels were measured using a chemiluminescence-based immunometric assay on an ADVIA Centaur immunoassay system (Siemens Healthcare Diagnostics Inc., Tarrytown, NY, USA).	up to 3 year

Collaborators and Investigators

• Sponsor: Shixuan Wang
• Collaborators: Sun Yat-sen University; Huazhong University of Science and Technology; Shanghai Jiao Tong University School of Medicine; Zhengzhou University; Xinjiang Medical University; Wuhan General Hospital of Guangzhou Military Command
• Investigators: Study Chair: Shixuan Wang, MD.PHD., Huazhong University of Science and Technology

Publications and helpful links

General Publications

• Wen J, Huang K, Du X, Zhang H, Ding T, Zhang C, Ma W, Zhong Y, Qu W, Liu Y, Li Z, Deng S, Luo A, Jin Y, Zhang J, Wang S. Can Inhibin B Reflect Ovarian Reserve of Healthy Reproductive Age Women Effectively? Front Endocrinol (Lausanne). 2021 Apr 14;12:626534. doi: 10.3389/fendo.2021.626534. eCollection 2021.
• Du X, Ding T, Zhang H, Zhang C, Ma W, Zhong Y, Qu W, Zheng J, Liu Y, Li Z, Huang K, Deng S, Ma L, Yang J, Jiang J, Yang S, Huang J, Wu M, Fang L, Lu Y, Luo A, Wang S. Age-Specific Normal Reference Range for Serum Anti-Mullerian Hormone in Healthy Chinese Han Women: A nationwide Population-Based Study. Reprod Sci. 2016 Aug;23(8):1019-27. doi: 10.1177/1933719115625843. Epub 2016 Jan 13.

Study record dates

Study Major Dates

• Study Start: July 1, 2011
• Primary Completion (Anticipated): May 1, 2016
• Study Completion (Anticipated): July 1, 2021

Study Registration Dates

• First Submitted: September 10, 2014
• First Submitted That Met QC Criteria: November 16, 2014
• First Posted (Estimate): November 19, 2014

Study Record Updates

• Last Update Posted (Estimate): April 27, 2016
• Last Update Submitted That Met QC Criteria: April 25, 2016
• Last Verified: April 1, 2016

More Information

Terms related to this study

• Keywords: female; ovarian function; Genital Function
• Additional Relevant MeSH Terms: Cardiovascular Diseases; Infertility; Infertility, Female
• Other Study ID Numbers: OA-1-female